PMID- 22093373
OWN - NLM
STAT- MEDLINE
DCOM- 20120425
LR  - 20210818
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Linking)
VI  - 13
IP  - 4
DP  - 2012 Apr
TI  - Strong serological responses and HIV RNA increase following AS03-adjuvanted 
      pandemic immunization in HIV-infected patients.
PG  - 207-18
LID - 10.1111/j.1468-1293.2011.00961.x [doi]
AB  - INTRODUCTION: We aimed to determine the antibody responses and effect on viral 
      load of the AS03-adjuvanted pandemic H1N1 vaccine in HIV-infected patients. 
      METHOD: A total of 121 HIV-infected patients and 138 healthy subjects were 
      enrolled in a prospective, open-label study. Healthy subjects received one dose 
      and HIV-infected patients two doses of the AS03-adjuvanted split influenza 
      A/09/H1N1 vaccine (Pandemrix(R); GlaxoSmithKline, Brentford, United Kingdom.) at an 
      interval of 3-4 weeks. The study was extended in 2010/2011 for 66 patients. 
      Geometric mean titres (GMTs), seroprotection rates (post-vaccination titre >/= 
      1:40) and HIV-1 RNA levels were measured before and 4 weeks after immunization. 
      RESULTS: After two immunizations, the seroprotection rate (94.2 vs. 87%, 
      respectively) and GMT (376 vs. 340, respectively) in HIV-infected patients were 
      as high as in healthy subjects after one dose, regardless of CD4 cell count. Four 
      weeks after immunization, HIV RNA was detected in plasma samples from 40 of 68 
      (58.0%) previously aviraemic patients [median 152 HIV-1 RNA copies/mL; 
      interquartile range (IQR) 87-509 copies/mL]. Subsequent measures indicated that 
      HIV RNA levels had again declined to <20 copies/mL in most patients (27 of 34; 
      79.4%). Following (nonadjuvanted) influenza immunization in 2010/2011, HIV RNA 
      levels only slightly increased (median final level 28 copies/mL) in three of 66 
      (4.5%) previously aviraemic patients, including two of 25 (8%) patients in whom 
      an increase had been elicited by AS03-adjuvanted vaccine the year before. 
      CONCLUSION: Most HIV-infected patients developed seroprotection after two doses 
      of AS03-adjuvanted pandemic vaccine. A transient effect on HIV RNA levels was 
      observed in previously aviraemic patients. A booster dose of the nonadjuvanted 
      influenza vaccine containing the A/09/H1N1 strain the following year did not 
      reproduce this finding, indicating a non-antigen-specific adjuvant effect.
CI  - (c) 2011 British HIV Association.
FAU - Calmy, A
AU  - Calmy A
AD  - Division of Infectious Diseases, HIV Unit, Department of Internal Medicine, 
      University Hospitals of Geneva, Switzerland. alexandra.calmy@hcuge.ch
FAU - Bel, M
AU  - Bel M
FAU - Nguyen, A
AU  - Nguyen A
FAU - Combescure, C
AU  - Combescure C
FAU - Delhumeau, C
AU  - Delhumeau C
FAU - Meier, S
AU  - Meier S
FAU - Yerly, S
AU  - Yerly S
FAU - Kaiser, L
AU  - Kaiser L
FAU - Hirschel, B
AU  - Hirschel B
FAU - Siegrist, C-A
AU  - Siegrist CA
CN  - H1N1 Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111107
PL  - England
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
RN  - 0 (Antibodies, Viral)
RN  - 0 (Drug Combinations)
RN  - 0 (Influenza Vaccines)
RN  - 0 (Polysorbates)
RN  - 0 (RNA, Viral)
RN  - 0 (pandemrix)
RN  - 7QWM220FJH (Squalene)
RN  - A7YT618XBV (AS03 adjuvant)
RN  - H4N855PNZ1 (alpha-Tocopherol)
SB  - IM
MH  - Adult
MH  - Antibodies, Viral/blood
MH  - Drug Combinations
MH  - Female
MH  - HIV Infections/*immunology/virology
MH  - HIV-1/isolation & purification
MH  - Hemagglutination Inhibition Tests
MH  - Humans
MH  - Influenza Vaccines/administration & dosage/*immunology
MH  - Male
MH  - Middle Aged
MH  - Polysorbates/administration & dosage
MH  - Prospective Studies
MH  - RNA, Viral/*blood
MH  - Squalene/administration & dosage/*immunology
MH  - Viral Load
MH  - alpha-Tocopherol/administration & dosage/*immunology
FIR - Siegrist, C A
IR  - Siegrist CA
FIR - Posfay-Barbe, K
IR  - Posfay-Barbe K
FIR - Meier, S
IR  - Meier S
FIR - Bel, M
IR  - Bel M
FIR - Grillet, S
IR  - Grillet S
FIR - Sealy, G
IR  - Sealy G
FIR - Demeules, J
IR  - Demeules J
FIR - Charvat, S
IR  - Charvat S
FIR - Verdon, M
IR  - Verdon M
FIR - Combescure, C
IR  - Combescure C
FIR - Hirschel, B
IR  - Hirschel B
FIR - Calmy, A
IR  - Calmy A
FIR - Nguyen, A
IR  - Nguyen A
FIR - Delhumeau-Cartier, C
IR  - Delhumeau-Cartier C
FIR - Gabay, C
IR  - Gabay C
FIR - Guerne, P A
IR  - Guerne PA
FIR - Seebach, J
IR  - Seebach J
FIR - Ribi, C
IR  - Ribi C
FIR - Villard, J
IR  - Villard J
FIR - Dietrich, P Y
IR  - Dietrich PY
FIR - George, A C
IR  - George AC
FIR - Favet, L
IR  - Favet L
FIR - van Delden, C
IR  - van Delden C
FIR - Morard, I
IR  - Morard I
FIR - Mentha, G
IR  - Mentha G
FIR - Giostra, E
IR  - Giostra E
FIR - Hadaya, K
IR  - Hadaya K
FIR - Martin, P Y
IR  - Martin PY
FIR - Soccal, P
IR  - Soccal P
FIR - Berney, T
IR  - Berney T
FIR - Noble, S
IR  - Noble S
FIR - Mohty, B
IR  - Mohty B
FIR - Nagy, M
IR  - Nagy M
FIR - Chalandon, Y
IR  - Chalandon Y
FIR - Roosnek, E
IR  - Roosnek E
FIR - Passweg, J
IR  - Passweg J
FIR - Kaiser, L
IR  - Kaiser L
FIR - Yerly, S
IR  - Yerly S
FIR - Thomas, Y
IR  - Thomas Y
FIR - Wunderli, W
IR  - Wunderli W
EDAT- 2011/11/19 06:00
MHDA- 2012/04/26 06:00
CRDT- 2011/11/19 06:00
PHST- 2011/08/15 00:00 [accepted]
PHST- 2011/11/19 06:00 [entrez]
PHST- 2011/11/19 06:00 [pubmed]
PHST- 2012/04/26 06:00 [medline]
AID - 10.1111/j.1468-1293.2011.00961.x [doi]
PST - ppublish
SO  - HIV Med. 2012 Apr;13(4):207-18. doi: 10.1111/j.1468-1293.2011.00961.x. Epub 2011 
      Nov 7.